• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Clinical Trial: FDA Stays Silent on Trovan Charges

Article

Pharmaceutical Executive

Pharmaceutical ExecutivePharmaceutical Executive-10-01-2001
Volume 0
Issue 0

Lagos, Nigeria-FDA refused to confirm or deny that it was launching a criminal investigation into Pfizer’s conduct during a 1996 clinical trial for Trovan (alatrofloxacin) in Nigerian patients.

Related Videos
Related Content